Key Takeaways Agonism Profile: Tirzepatide is a dual GLP-1/GIP agonist, while Retatrutide is a "triple agonist" targeting GLP-1, GIP, and Glucagon receptors
Without testing, there is no way to distinguish between B12 deficiency and other causes of similar symptoms, no way to determine the severity of deficiency, and no way to select the most appropriate delivery method
YOU MAY UNSUBSCRIBE AT ANY TIME.
The report highlights early metabolic studies, selected clinical trials, and certain double-blind placebo-controlled investigations that examined markers such as: blood sugar regulation insulin sensitivity cholesterol levels impaired glucose tolerance adipose tissue activity fat release and lipolytic activity While these studies generated interest in AOD-9604 as a potential anti-obesity drug candidate , the report stresses that no authority recognizes it as an active treatment for obesity, weight loss, or human use and emphasizes that it remains designated strictly for research use
Yes, but only cosmetically
Our gut is responsible for producing a huge percentage of our neurotransmitters, including serotonin
